These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7517992)

  • 21. Increasing level of prostate-specific antigen and prostate cancer risk factors among 193 men examined in screening procedure.
    Opalińska E; Michalak A; Stoma F; Latalski M; Goniewicz M
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):57-63. PubMed ID: 15323167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
    J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
    Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
    Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer: enthusiasm for screening.
    Kaye KW
    Med J Aust; 1995 May; 162(10):540-1. PubMed ID: 7539884
    [No Abstract]   [Full Text] [Related]  

  • 26. The case for prostate cancer screening.
    Andriole GL
    Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSA screening: the bottom line.
    Elhilali MM
    CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
    [No Abstract]   [Full Text] [Related]  

  • 29. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum prostate specific antigen for the early detection of prostate cancer in outpatients of internal medicine].
    Otani T; Hayashi Y; Ikuno Y; Hirao Y; Ozono S; Okajima E
    Hinyokika Kiyo; 1996 Sep; 42(9):645-9. PubMed ID: 8918662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
    Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
    Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
    J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 34. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Screening for prostatic cancer].
    Pushkar' DIu; Govorov AV; Bormotin AV
    Urologiia; 2003; (1):10-5. PubMed ID: 12621959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for prostate cancer in 2006: PSA in the 21st century.
    Maroni PD; Crawford ED
    N C Med J; 2006; 67(2):136-9. PubMed ID: 16752718
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
    Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early detection of prostate cancer: is PSA a reliable option?
    Okihara K; Babaian RJ
    Tex Med; 2001 Feb; 97(2):59-62. PubMed ID: 11233061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.